Literature DB >> 21757231

Disease progression mechanism in myelodysplastic syndromes: insight into the role of the microenvironment.

Mariko Ishibashi1, Hideto Tamura, Kiyoyuki Ogata.   

Abstract

The somatic mutation theory proposing that a sequential accumulation of genetic abnormalities plays a major role in cancer pathogenesis has not yet been confirmed for myelodysplastic syndromes (MDS). Meanwhile, recent data in some cancers has underscored the role of the microenvironment in tumor growth. MDS CD34+CD38- cells usually fail to repopulate after transplantation in mice, suggesting the importance of the microenvironment for MDS cells. Our recent data have provided a disease-progression model in which overproduction of interferon-γ and tumor necrosis factor-α in the microenvironment is the primary event. This causes B7-H1 molecule expression on MDS blasts, which generates a bifunctional signal inducing T-cell apoptosis and enhancing blast proliferation. The latter may provide more opportunity for developing secondary genetic changes.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757231     DOI: 10.1016/j.leukres.2011.06.022

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

1.  Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate.

Authors:  Johanna Zannoni; Natacha Mauz; Landry Seyve; Mathieu Meunier; Karin Pernet-Gallay; Julie Brault; Claire Jouzier; David Laurin; Mylène Pezet; Martine Pernollet; Jean-Yves Cahn; Fabrice Cognasse; Benoît Polack; Sophie Park
Journal:  Blood Adv       Date:  2019-06-25

2.  Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.

Authors:  Ruben A Ferrer; Manja Wobus; Catrin List; Rebekka Wehner; Claudia Schönefeldt; Barbara Brocard; Brigitte Mohr; Martina Rauner; Marc Schmitz; Maik Stiehler; Gerhard Ehninger; Lorenz C Hofbauer; Martin Bornhäuser; Uwe Platzbecker
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

Review 3.  TNF-α, a good or bad factor in hematological diseases?

Authors:  Tian Tian; Min Wang; Daoxin Ma
Journal:  Stem Cell Investig       Date:  2014-06-01

4.  Impaired osteogenic differentiation of mesenchymal stem cells derived from bone marrow of patients with lower-risk myelodysplastic syndromes.

Authors:  Chengming Fei; Youshan Zhao; Shucheng Gu; Juan Guo; Xi Zhang; Xiao Li; Chunkang Chang
Journal:  Tumour Biol       Date:  2014-01-19

5.  Relationship of HIF‑1α expression with apoptosis and cell cycle in bone marrow mesenchymal stem cells from patients with myelodysplastic syndrome.

Authors:  Beibei Qu; Xiuhua Han; Lan Zhao; Feifei Zhang; Qingmei Gao
Journal:  Mol Med Rep       Date:  2022-06-01       Impact factor: 3.423

Review 6.  Myelodysplasia is in the niche: novel concepts and emerging therapies.

Authors:  E Bulycheva; M Rauner; H Medyouf; I Theurl; M Bornhäuser; L C Hofbauer; U Platzbecker
Journal:  Leukemia       Date:  2014-11-14       Impact factor: 11.528

Review 7.  Controversies on the Consequences of Iron Overload and Chelation in MDS.

Authors:  Francesca Vinchi; Saskia Hell; Uwe Platzbecker
Journal:  Hemasphere       Date:  2020-05-27

8.  [Identification of miR-639 expression in myelodysplastic syndrome and its target gene prediction].

Authors:  X P Zhang; Y Huang; H Y Li; J Wen; D H Deng; P Cheng; W H Zhao; J Luo; Y R Lai; Z F Liu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-02-14

9.  BMI1 reprogrammes histone acetylation and enhances c-fos pathway via directly binding to Zmym3 in malignant myeloid progression.

Authors:  Hongjie Shen; Zixing Chen; Xin Ding; Xiaofei Qi; Jiannong Cen; Yuanyuan Wang; Li Yao; Yan Chen
Journal:  J Cell Mol Med       Date:  2014-02-27       Impact factor: 5.310

10.  Utilizing network pharmacology to explore potential mechanisms of YiSui NongJian formula in treating myelodysplastic syndrome.

Authors:  Lerong Qin; Haiyan Chen; Xiaoqing Ding; Ming Guo; Haiyan Lang; Junxia Liu; Ling Li; Jing Liao; Junyao Liao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.